Keros Therapeutics (KROS) Accounts Payables (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Accounts Payables came in at $2.0 million in Q4 2025, down 57.26% YoY from $4.6 million in Q4 2024, and down 14.4% on a QoQ basis from $2.3 million in Q3 2025.
Keros Therapeutics (KROS) Accounts Payables (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Accounts Payables data on file, last reported at $2.0 million in Q4 2025.
- Quarterly Accounts Payables fell 57.26% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.0 million (down 57.26% YoY) and the FY2025 annual result came in at $2.0 million, down 57.26% from the prior year.
- Accounts Payables retreated to $2.0 million in Q4 2025, from $2.3 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $7.7 million in Q2 2022 to a low of $1.4 million in Q2 2021.
- A 5-year average of $4.1 million and a median of $4.0 million in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2021 — Accounts Payables plunged 71.72% — and 2022, when it surged 458.31%.
- Tracing KROS's Accounts Payables over 5 years: stood at $3.6 million in 2021, then declined by 8.4% to $3.3 million in 2022, then jumped by 63.22% to $5.4 million in 2023, then slipped by 15.56% to $4.6 million in 2024, then plunged by 57.26% to $2.0 million in 2025.
- The last three Accounts Payables figures came in at $2.0 million (Q4 2025), $2.3 million (Q3 2025), and $5.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | 1.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.82 Mn |
| Dec 31, 2025 | 1.97 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 5.27 Mn |
| Mar 31, 2025 | 6.64 Mn |
| Dec 31, 2024 | 4.60 Mn |
| Sep 30, 2024 | 4.98 Mn |
| Jun 30, 2024 | 6.54 Mn |
| Mar 31, 2024 | 4.99 Mn |
| Dec 31, 2023 | 5.45 Mn |
| Sep 30, 2023 | 3.87 Mn |
| Jun 30, 2023 | 4.15 Mn |
| Mar 31, 2023 | 4.68 Mn |
| Dec 31, 2022 | 3.34 Mn |
| Sep 30, 2022 | 2.66 Mn |
| Jun 30, 2022 | 7.66 Mn |
| Mar 31, 2022 | 3.06 Mn |
| Dec 31, 2021 | 3.65 Mn |
| Sep 30, 2021 | 2.81 Mn |
| Jun 30, 2021 | 1.37 Mn |